Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
1. Alvotech partnered with Dr. Reddy's to develop a Keytruda biosimilar globally. 2. Keytruda had $29.5 billion in worldwide sales in 2024. 3. The collaboration enhances manufacturing and commercialization capabilities for biosimilars. 4. Alvotech's recent FDA approvals boost its position in the biosimilar market. 5. Technical analysis indicates potential bullish sentiment for ALVO in the long term.